2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

3243 Clearance of acute myeloid leukemia-derived cell lines and human PDX grafts in mice by memory-like natural killer cells engaged by a triplebody

Ezhilarasi Chendamarai, PhD, Michael P. Rettig, PhD2, Julie Ritchey3, Dilan Anil Patel, MD4, Susan Gladney5, Hannah Quon6, Gayla Hadwiger7, William Chin, MD8, Todd A Braciak, MD9, Katja Klausz, PhD10, Dorothee Winterberg, PhD11, Matija Peterlin, MD12, Michelle Becker-Hapak13, Lynne Marsala14, Matthias Peipp, PhD15, Georg Fey, MD16, Todd Fehniger, MD, PhD17, John F. DiPersio, MD18
1 Washington University In Saint Louis, Saint Louis, Missouri, United States
2 Washington University In Saint Louis, Saint Louis, Missouri, United States
3 Washington University In Saint Louis, Saint Louis, Missouri, United States
4 Washington University In Saint Louis, Saint Louis, Missouri, United States
5 Washington University In Saint Louis, Saint Louis, Missouri, United States
6 Washington University In Saint Louis, Saint Louis, Missouri, United States
7 Washington University In Saint Louis, Saint Louis, Missouri, United States
8 Harvard Medical School, Boston, Massachusetts, United States
9 KOSMAS, Nurnberg, Germany
10 Universität Kiel, Kiel, Germany
11 Universität Kiel, Kiel, Germany
12 University of California San Francisco, San Francisco, California, United States
13 Washington University In Saint Louis, Saint Louis, Missouri, United States
14 Washington University In Saint Louis, Saint Louis, Missouri, United States
15 University of Kiel, Kiel, Germany
16 KOSMAS, Nurnberg, Germany
17 Washington University In Saint Louis, Saint Louis, Missouri, United States
18 Washington University In Saint Louis, Saint Louis, Missouri, United States

Introduction: Immunotherapies for the approximately two-thirds of patients with relapsed or primary refractory acute myeloid leukemia (AML) are limited by target antigen specificity and effector cell toxicities. To our knowledge, no studies have investigated cytokine-induced memory-like natural killer cells (CIML- or ML-NK) combined with the novel, off-the-shelf trispecific antibody, KT1 (CD33 x CD16 x CD123) in animal models. We hypothesized that KT1 would facilitate immune-mediated clearance of human AML cell lines and patient derived AML xenografts (PDX) expressing similar antigen density of CD33 and CD123.

Methods: We report in vivo experiments evaluating ML-NK cells against CD33+/CD123+ THP1 (Click Beetle Red luciferase-GFP expressing THP1) cells and with ML-NK cells with a patient derived AML xenograft (PDX) model (UPN247669) with and without KT1. Mice were assessed daily and weighed weekly.

Non-mobilized healthy donor leukapheresis products were enriched for conventional NK (cNK) cells via CD3-depletion and CD56 positive selection (> 90% purity) and viably cryopreserved. Frozen cNK cells were thawed, activated with IL12, IL15, and IL18 for 12-16 hours to initiate ML-NK cell programs, washed, and injected. In this situation, ML-NK cells expand in vivo in NSG xenografted mice. THP1 cells were used in the first experiment with IL15 transgenic NSG mice. Treatment groups included controls (THP1 alone and THP1 + KT1, n = 5 each) and experimental (THP1 + ML-NK and THP1 + ML-NK + KT1, n = 5 each). Twenty micrograms KT1 were injected daily intraperitoneally (i.p.) from days 0 to 21. Recombinant human interleukin-2 (rhIL2, 50,000 IU/mouse) was administered 3x/week for 3 weeks. ML-NK cells were obtained from two different donors (UPN498, n = 3, and UPN930, n = 2). Moribund mice were euthanized and bone marrow, spleen, and extramedullary tumors harvested and assessed by FACS for GFP+ tumors as well as CD33 and CD123 expression on the relapsing tumors.

In the subsequent human PDX experiment, NSG-SGM3 mice received 250 cGy total body irradiation on day -2 followed by 2 x 106 tail vein injection of AML cells (UPN247669) followed by the same schedule and dose of KT1 above. Recombinant human IL-15 (rhIL15, 10 ng/dose) was administered every 2 days for 4 weeks along with rhIL2 (noted above). ML-NK cells from a single donor (UPN930) were injected on days 0 and 7 (1 x 107 tail vein injection). Treatment groups included controls (AML only, AML + KT1, AML + ML-NK, n = 5 each) and experimental (AML + CIML-NK + KT1, n = 10).

Results: For THP1 cells, KT1 combined with ML-NK provided a significant survival advantage compared to the other groups (p = 0.002). BLI showed lack of tumor growth on days 4-7 followed by increasing signal. ML-NK cells alone did not control tumor following injection. Notably, while both ML-NK donors combined with KT1 showed tumor reduction, donor UPN930 exhibited more pronounced benefit. Tumor clearance was most pronounced in the bone marrow with extramedullary relapse contributing to bulk of BLI signal and eventual mortality.

NSG-S mice were chosen because primary human AML showed delayed engraftment in IL15 transgenic mice (78 versus 30 days, respectively). ML-NK + KT1 showed a statistically significant survival advantage over untreated tumor alone and non-significant difference versus ML-NK (39 vs 30 days and 39 vs 32 days, respectively). Combination therapy demonstrated effective leukemia control with significantly reduced circulating tumor compared to both untreated group (2.76 vs. 34.8%, p = 0.001) and the ML-NK alone group (2.76 vs. 11.3% p = 0.004) and detectable circulating NK cells on days 21 and by FACS.  At euthanasia, human NK cells were detected in peripheral blood though not spleen or bone marrow.

Unlike the monocytic THP1 cell line, PDX tumors did not engraft in the liver. No liver or subcutaneous extramedullary tumors noted at relapse. One extramedullary renal tumor noted in the experimental group. Neither CD33 nor CD123 expression was lost in the relapsing tumors, suggesting alternative mechanisms of progressive disease, such as HLA-E expression (49% on UPN669) or aggressiveness of AML PDX model combined with lack of physiologic IL15.

Conclusion: KT1 shows promising anti-leukemic efficacy particularly for medullary disease eradication in uniformly fatal cell line and PDX models. Future studies are needed to assess the mechanism and treatment of extramedullary relapse.

Ezhilarasi Chendamarai, PhD: No relevant conflicts of interest to declare.